MLEC vs RKDA

For growth investors, Moolec Science S.

A. (MLEC) is the stronger pick with 58. 3% revenue growth year-over-year, versus -3. 7% for Arcadia Biosciences, Inc. (RKDA). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Moolec Science S.

A. (MLEC) delivered a total return of -8. 0%, compared to -98. 9% for Arcadia Biosciences, Inc. (RKDA). Over 10 years, the gap is even starker: MLEC returned -8. 5% versus RKDA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Moolec Science S.

A. (MLEC) is the lower-risk stock at 0. 89β versus Arcadia Biosciences, Inc. 's 0. 98β — meaning RKDA is approximately 11% more volatile than MLEC relative to the S&P 500.

By revenue growth (latest reported year), Moolec Science S.

A. (MLEC) is pulling ahead at 58. 3% versus -3. 7% for Arcadia Biosciences, Inc. (RKDA). On earnings-per-share growth, the picture is similar: Arcadia Biosciences, Inc. grew EPS 66. 9% year-over-year, compared to -89. 8% for Moolec Science S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Moolec Science S.

A. (MLEC) is the more profitable company, earning -33. 4% net margin versus -48. 1% for Arcadia Biosciences, Inc. — meaning it keeps -33. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MLEC leads at -3. 1% versus -205. 7% for RKDA. At the gross margin level — before operating expenses — RKDA leads at 36. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Moolec Science S.

A. (MLEC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 89)). Both have compounded well over 10 years (MLEC: -8. 5%, RKDA: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MLEC (Healthcare) and RKDA (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MLEC is a small-cap high-growth stock; RKDA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.